Van ECK Associates Corp Has $8.93 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Van ECK Associates Corp cut its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,380 shares of the medical research company's stock after selling 2,893 shares during the period. Van ECK Associates Corp owned 0.09% of Charles River Laboratories International worth $8,931,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Empirical Finance LLC lifted its position in shares of Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after purchasing an additional 53 shares in the last quarter. OLD National Bancorp IN lifted its position in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after purchasing an additional 59 shares in the last quarter. Fiduciary Financial Group LLC lifted its position in shares of Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after purchasing an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Finally, M&T Bank Corp lifted its position in shares of Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock worth $394,000 after purchasing an additional 66 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CRL has been the topic of several analyst reports. The Goldman Sachs Group cut their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. TD Cowen upped their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Finally, StockNews.com downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $195.71.

Charles River Laboratories International Stock Down 1.4 %

Charles River Laboratories International stock traded down $2.37 during mid-day trading on Thursday, reaching $162.63. The company's stock had a trading volume of 1,804,636 shares, compared to its average volume of 1,055,758. The company has a market capitalization of $8.32 billion, a price-to-earnings ratio of 20.35, a price-to-earnings-growth ratio of 6.01 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00. The business's 50 day simple moving average is $174.02 and its 200 day simple moving average is $188.99. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.46 earnings per share. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 10.16 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).